Investor Relations

Arbutus Biopharma is a publicly-traded (NASDAQ:ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). We are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the HBV treatment landscape and cure hepatitis B virus disease.

View all »   RSSRecent Releases

May 22, 2017
Arbutus Presents HBV Drug Combination Studies at ICAR

May 4, 2017
Arbutus Announces Corporate Update and First Quarter 2017 Financial Results


View all »Events & Presentations

May 24, 2017
AGM Proxy Statement

May 22, 2017
ICAR 2017